News
Eurand Announces Launch of OTC Unisom SleepMelts by Chattem
Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that Chattem, Inc. ("Chattem") has launched a new orally disintegrating tablet ("ODT") formulation of its popular over-the-counter (OTC) sleep-aid brand, Unisom(r).
Unisom(r) SleepMelts(tm), which contains 25mg of diphenhydramine hydrochloride, was developed by Eurand using its AdvaTab(r) and Microcaps(r) taste-masking technologies. The product was developed as part of the EUR-1047 program. Unisom(r) SleepMelts(tm), an OTC sleep-aid, is now available in leading U.S. mass merchandiser, drug and food retailers. Eurand will exclusively supply the product for Chattem, which will be manufactured at Eurand's U.S. facility in Vandalia, OH.
Gearoid Faherty, Chief Executive Officer of Eurand, commented, "We are pleased to complete the development and witness the launch of our diphenhydramine ODT product under Chattem's Unisom(r) brand name. Chattem is a leading marketer of OTC healthcare brands and we are looking forward to working with them on the successful commercialization of this product in the U.S. The launch of Unisom(r) SleepMelts(tm) represents the first product to be commercialized using our AdvaTab ODT technology and is further evidence of the strength of our drug formulation technology and development capabilities."